Carding et al. (2026)
- Authors: Simon Carding, 21 International Partners
- Institutes: Quadram Institute Bioscience, Norwich, UK, University of East Anglia, UK, European ME Research Group (EMERG)
- Publisher: European Commission (Horizon Europe)
- Link: DOI
Summary
This landmark €7.5 million EU-funded project represents one of the largest coordinated efforts to resolve the biological heterogeneity of ME/CFS through patient stratification. By identifying distinct molecular subgroups, the study aims to move the field toward personalized medicine and more effective clinical trials. The scale of the consortium suggests a significant shift in European research priority and infrastructure for post-infectious chronic illnesses.
What was researched?
The DISCOVER-ME project investigates the biological basis of ME/CFS using large-scale multi-omics data to identify specific patient subtypes. It focuses on characterizing the physiological differences between patients to enable more precise diagnosis and targeted treatment strategies.
Why was it researched?
ME/CFS is a highly heterogeneous condition, making it difficult to find universal biomarkers or treatments that work for every patient. Researchers aim to solve this by ‘stratifying’ patients into groups based on their unique molecular signatures, such as immune or metabolic profiles.
How was it researched?
The project involves a consortium of 21 partners across Europe and North America utilizing high-throughput ‘omics’ technologies, including genomics, transcriptomics, and microbiome analysis. The study leverages existing biobanks and harmonized clinical data to ensure robust findings across a large, diverse cohort of patients.
What has been found?
As a newly funded initiative, the project focuses on the systematic integration of disparate biological data sets to identify common patterns in ME/CFS pathology. Initial goals include establishing standardized biobanking protocols and identifying the most promising molecular markers for patient classification.
Discussion
A major challenge for the project is ensuring that samples are properly pre-stratified by factors like disease severity and the presence of post-exertional malaise. Success depends on the consortium’s ability to minimize biological ‘noise’ through rigorous data harmonization across international sites.
Conclusion & Future Work
The DISCOVER-ME project is expected to provide the framework for the next generation of ME/CFS research and clinical care. Future efforts will likely focus on validating these subgroups in independent cohorts and testing subgroup-specific therapies.